- The Dish’s Weekly Biotechnology News Wrap Up – April 21, 2017Posted 5 days ago
- Glycosylation Overview and How to Control Glycosylation using In Vitro GlycoengineeringPosted 7 days ago
- A Novel Approach for Expansion of High Quality Mesenchymal Stem CellsPosted 1 week ago
- Cell Therapy Clinical Trials: Navigating the operational shift from Phase 1 to Phase 2Posted 1 week ago
- The Dish’s Weekly Biotechnology News Wrap Up – April 14, 2017Posted 2 weeks ago
- GMP Proteins for Cell Therapy Manufacturing: Top 6 Things to KnowPosted 2 weeks ago
- Smart Cell Culture Monitoring – Transforming the way we look at cells in culturePosted 2 weeks ago
- A Primer on Primary Cells and CulturePosted 2 weeks ago
- The Importance of Resin Selection in Development of a Platform Bioprocess FilmPosted 2 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – April 7, 2017Posted 3 weeks ago
The future of cell culture development? Part I
As we learn more and more about the detailed workings of cells used in biomanufacturing, methods to modify these workings are developed. This recent article from GEN describes some technologies that were unavailable to cell culture scientists in the past; glycoengineering and site-specific integration.
The sequencing of the CHO genome should provide even more opportunities to improve biopharmaceutical production. Several groups have sequenced CHO cell lines; GT Life Sciences collaborated with BGI to sequence CHO-K1 [announcement pdf], while Selexis collaborated with several Swiss institutions to sequence their proprietary “SURECHO-M” line.
These are just a few examples of techniques that can be used to develop cell lines to produce biopharmaceuticals. It should be interesting to see how regulatory agencies treat drug applications that use cell lines that were developed using advanced techniques such as these.